Qadir Dhilshad, Chua Monica, Sulaiman Suzanna
Department of Obstetrics and Gynaecology, KK Women's and Children's Hospital, Singapore.
BMJ Case Rep. 2019 Aug 30;12(8):e230635. doi: 10.1136/bcr-2019-230635.
Tamoxifen is a selective oestrogen receptor modulator widely used in breast cancer treatment, with good survival rates. Its partial agonist action on other tissues such as the uterus, however, promotes the development of endometrial hyperplasia and cancer. It appears that tamoxifen does not alter the age of menopause and women may still get pregnant while on tamoxifen. We present the case of a 47-year-old Chinese woman with breast cancer on tamoxifen, who presented with one episode of heavy per vaginal bleeding after 2 years of amenorrhoea. Her urine pregnancy test was negative and the ultrasound scan was suspicious for malignancy. She underwent a hysteroscopic evaluation for abnormal bleeding on tamoxifen. Histopathology confirmed products of conception. This case illustrates the importance of understanding the rise and decline of human chorionic gonadotropin in pregnancy, as well as the pivotal role of contraception despite having amenorrhoea on tamoxifen.
他莫昔芬是一种广泛用于乳腺癌治疗的选择性雌激素受体调节剂,生存率良好。然而,它对子宫等其他组织的部分激动剂作用会促进子宫内膜增生和癌症的发展。他莫昔芬似乎不会改变绝经年龄,女性在服用他莫昔芬期间仍可能怀孕。我们报告一例47岁患有乳腺癌且正在服用他莫昔芬的中国女性病例,该患者在闭经2年后出现一次严重的经阴道大出血。她的尿妊娠试验为阴性,超声扫描怀疑有恶性病变。她因服用他莫昔芬后出现异常出血接受了宫腔镜评估。组织病理学证实为妊娠产物。该病例说明了了解孕期人绒毛膜促性腺激素升降的重要性,以及尽管服用他莫昔芬出现闭经但避孕仍起关键作用。